German biotech firm BioNTech announced its agreement to acquire all shares of domestic peer CureVac in an all-stock deal valued at approximately $1.25 billion. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech American Depositary Shares (ADSs).
CureVac shareholders are expected to own between 4% and 6% of BioNTech upon the closing of the acquisition. This strategic move aims to strengthen BioNTech's mRNA cancer immunotherapy portfolio by integrating CureVac's research and manufacturing site in Tübingen.
The transaction was unanimously approved by both BioNTech's and CureVac's management and supervisory boards and is expected to close in 2025. This acquisition is intended to combine complementary scientific capabilities and proprietary technologies to advance mRNA-based cancer treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.